Suppr超能文献

一种预测大细胞肺癌患者总生存期的新型列线图的开发与验证:一项基于监测、流行病学和最终结果人群的研究。

Development and validation of a novel nomogram to predict the overall survival of patients with large cell lung cancer: A surveillance, epidemiology, and end results population-based study.

作者信息

Zhou Hongxia, Gao Pengxiang, Liu Fangpeng, Shi Liangliang, Sun Longhua, Zhang Wei, Xu Xinping, Liu Xiujuan

机构信息

Department of Nephrology, The 908th Hospital of the People's Liberation Army Joint Logistics Support Force, The Great Wall Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi 330006, China.

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province 330006, China.

出版信息

Heliyon. 2023 May 6;9(5):e15924. doi: 10.1016/j.heliyon.2023.e15924. eCollection 2023 May.

Abstract

BACKGROUND

Large cell lung cancer (LCLC) is a rare subtype of non-small cell lung carcinoma (NSCLC), and little is known about its clinical and biological characteristics.

METHODS

LCLC patient data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. All patients were randomly divided into a training group and a validation group at a ratio of 7:3. The independent prognostic factors that were identified (P < 0.01) by stepwise multivariate Cox analysis were incorporated into an overall survival (OS) prediction nomogram, and risk-stratification systems, C-index, time-ROC, calibration curve, and decision curve analysis (DCA) were applied to evaluate the quality of the model.

RESULTS

Nine factors were incorporated into the nomogram: age, sex, race, marital status, 6th AJCC stage, chemotherapy, radiation, surgery and tumor size. The C-index of the predicting OS model in the training dataset and in the test dataset was 0.757 ± 0.006 and 0.764 ± 0.009, respectively. The time-AUCs exceeded 0.8. The DCA curve showed that the nomogram has better clinical value than the TNM staging system.

CONCLUSIONS

Our study summarized the clinical characteristics and survival probability of LCLC patients, and a visual nomogram was developed to predict the 1-year, 3-year and 5-year OS of LCLC patients. This provides more accurate OS assessments for LCLC patients and helps clinicians make personal management decisions.

摘要

背景

大细胞肺癌(LCLC)是非小细胞肺癌(NSCLC)的一种罕见亚型,对其临床和生物学特征了解甚少。

方法

从2004年至2015年的监测、流行病学和最终结果(SEER)数据库中提取LCLC患者数据。所有患者按7:3的比例随机分为训练组和验证组。通过逐步多变量Cox分析确定的独立预后因素(P < 0.01)被纳入总生存(OS)预测列线图,并应用风险分层系统、C指数、时间ROC、校准曲线和决策曲线分析(DCA)来评估模型质量。

结果

九个因素被纳入列线图:年龄、性别、种族、婚姻状况、美国癌症联合委员会(AJCC)第6版分期、化疗、放疗、手术和肿瘤大小。训练数据集和测试数据集中预测OS模型的C指数分别为0.757 ± 0.006和0.764 ± 0.009。时间AUC超过0.8。DCA曲线表明列线图比TNM分期系统具有更好的临床价值。

结论

我们的研究总结了LCLC患者的临床特征和生存概率,并开发了一个可视化列线图来预测LCLC患者的1年、3年和5年总生存。这为LCLC患者提供了更准确的总生存评估,并帮助临床医生做出个性化管理决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea39/10200837/e0d670cf82d2/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验